Vitamin D: What the Evidence Actually Shows, and Why the Guidelines Are Still Debated

Few nutrients have as contentious a research history as vitamin D. A 2025 review in Nutrients, written partly in response to the 2024 Endocrine Society guidelines, makes a pointed argument: most vitamin D randomized controlled trials have failed to show benefits not because vitamin D doesn’t work, but because of how those trials were designed — and the review makes the case for weighing observational evidence more heavily instead.

How Widespread Is Deficiency, Really

Vitamin D deficiency (blood levels below 20 ng/mL) is estimated at 45% globally for 2000–2022, ranging from 57% at high latitudes (60–80°N) to 18% closer to the equator (20–60°N). In the U.S., roughly 25% of the population has levels below 20 ng/mL, and 60% of Central Europeans fall below that threshold — genuinely widespread, not a niche concern.

Why Vitamin D Trials Keep Coming Up Empty

The review’s central methodological argument: pharmaceutical-style RCTs are poorly suited to testing a nutrient like vitamin D. Most vitamin D trials enrolled participants who already had adequate blood levels (≥30 ng/mL) going in — meaning there was little room for the treatment group to improve — and frequently allowed the “placebo” control group to take 600–800 IU/day on their own, blurring the comparison. A 2014 set of guidelines for nutrient RCTs specifically recommends enrolling only people with low starting levels and supplementing enough to actually raise them into the range associated with benefit — the review notes almost no vitamin D trial has followed this properly.

What the Observational Evidence Shows

Large prospective cohort studies — which follow big populations over years and track health outcomes against measured vitamin D levels — form the basis of most of this review’s recommendations, with a consistent finding: serum 25(OH)D concentrations above 30 ng/mL (75 nmol/L) are associated with significantly lower disease and mortality risk compared with levels below 20 ng/mL, across 8 of the 10 leading causes of death in the U.S. — including heart disease, cancer, COVID-19, stroke, chronic respiratory disease, Alzheimer’s disease, diabetes, and kidney disease.

Cardiovascular Disease

Vitamin D is linked to cardiovascular benefits partly through its role in calcium homeostasis and gene transcription that supports heart muscle contractility and reduces cardiac hypertrophy and atherosclerosis risk. Meta-analyses of RCTs have found vitamin D supplementation significantly increases HDL cholesterol and reduces triglycerides and systolic blood pressure — real risk-factor improvements, even without a hard mortality endpoint proven in trials.

What Dose Actually Gets People to a Healthy Level

A consensus statement from 27 vitamin D researchers recommends supplementation of up to 2000 IU/day, sufficient to raise and maintain 25(OH)D above 20 ng/mL in over 99% of adults and above 30 ng/mL in over 90%. This review’s authors go further, suggesting that a daily dose between 4000 and 6000 IU of vitamin D₃ would provide even greater protection by achieving serum levels of 40–70 ng/mL — notably higher than the more conservative 600–800 IU/day still recommended by some official guidelines.

The Bottom Line

This review’s core argument is a methodological one worth understanding on its own terms: vitamin D research is caught between RCT standards built for pharmaceuticals (which have largely failed to detect benefit, arguably due to design flaws) and a large body of observational data showing a consistent, dose-related association between higher vitamin D status and lower disease risk. The practical recommendation that follows — daily supplementation in the 2000–6000 IU range depending on starting levels — is more assertive than some official guidelines, and the review is explicit that future guidelines should better integrate observational and RCT evidence rather than dismissing the former.

References
[1] Grant, W.B.; Wimalawansa, S.J.; Pludowski, P.; Cheng, R.Z. “Vitamin D: Evidence-Based Health Benefits and Recommendations for Population Guidelines.” Nutrients 2025, 17, 277. https://doi.org/10.3390/nu17020277 (open access)